Breaking News Instant updates and real-time market news.

VRAY

ViewRay

$8.24

0.18 (2.23%)

, TNP

TEN, Ltd.

$3.41

0.04 (1.19%)

20:25
03/11/18
03/11
20:25
03/11/18
20:25

Notable companies reporting before Monday's open

Notable companies reporting before Monday's open, with earnings consensus, include ViewRay (VRAY), consensus (15c)... Tsakos Energy Navigation (TNP), consensus (5c)... Qudian (QD), consensus 27c... Minerva Neurosciences (NERV), consensus (38c)... Egalet (EGLT), consensus (38c)... Aclaris Therapeutics (ACRS), consensus (49c).

VRAY

ViewRay

$8.24

0.18 (2.23%)

TNP

TEN, Ltd.

$3.41

0.04 (1.19%)

QD

Qudian

$15.85

-1.01 (-5.99%)

NERV

Minerva

$5.75

0.2 (3.60%)

EGLT

Egalet

$0.75

0.02 (2.74%)

ACRS

Aclaris Therapeutics

$21.28

0.72 (3.50%)

  • 12

    Mar

  • 12

    Mar

  • 12

    Mar

  • 12

    Mar

  • 12

    Mar

  • 12

    Mar

  • 12

    Mar

  • 12

    Mar

  • 13

    Mar

  • 03

    May

VRAY ViewRay
$8.24

0.18 (2.23%)

02/08/18
RILY
02/08/18
INITIATION
Target $13.5
RILY
Buy
ViewRay initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started ViewRay with a Buy rating and $13.50 price target. The analyst believes the company's MRI-guided Linac systems could "meaningfully disrupt" the radiation therapy market.
01/04/18
CANT
01/04/18
INITIATION
Target $13
CANT
Overweight
ViewRay assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of ViewRay with an Overweight rating and $13 price target.
09/06/17
MZHO
09/06/17
INITIATION
Target $12
MZHO
Buy
ViewRay initiated with a Buy at Mizuho
Mizuho initiated ViewRay with a Buy and a $12 price target.
07/20/17
AGIS
07/20/17
INITIATION
Target $11
AGIS
Buy
ViewRay assumed with a Buy at Aegis
Aegis analyst Benjamin Haynor assumed coverage of ViewRay with a Buy rating and $11 price target. The analyst views the company's MRIdian MRI-guided radiation oncology platform as unique and believes it should should allow the expansion of treatable tumors.
TNP TEN, Ltd.
$3.41

0.04 (1.19%)

08/02/17
WELS
08/02/17
DOWNGRADE
Target $3.25
WELS
Market Perform
TEN Ltd. downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded TEN Ltd to Market Perform from Outperform and reduced its price target to $3.25 from $5. Analyst Michael Webber said demand headwinds from OPEC, US production, ect, and Q2 newbuild orders will likely push an industry sustained day rate recovery into 2019.
09/18/17
MAXM
09/18/17
NO CHANGE
MAXM
TEN Ltd. should be bought on weakness, says Maxim
Maxim analyst James Jang says that TEN's valuation is "compelling" due to what he sees as its "high charter cover and fixed dividend payment." The analyst, noting that the company's ship building program has ended, expects it to reduce its debt, making its balance sheet more attractive. He trimmed his price target on the stock to $6 from $7, citing his belief that asset values will "lag through 2018." However, he recommends buying the shares on weakness.
12/18/17
JEFF
12/18/17
INITIATION
Target $6
JEFF
Buy
TEN, Ltd. assumed with a Buy at Jefferies
Jefferies analyst Randy Giveans assumed coverage of TEN, Ltd. with a Buy rating and $8 price target. The analyst assumed coverage of 23 energy maritime shipping names saying the industry is "primed for significant improvement." For the first time in 10 years, the analyst expects capacity shortages with demand growth to outpace supply growth in every shipping sector in 2018.
01/19/18
JPMS
01/19/18
DOWNGRADE
JPMS
Neutral
Navios Acquisition downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Noah Parquette downgraded Navios Maritime Acquisition (NNA) to Neutral on concerns the dividend could be cut if his rate forecasts prove to be correct. He believes 2018 could be a tough year for crude tankers as demand weakness persists. The analyst does not have a price target for Navios Acquisition shares. His favorite names among the Oil Tankers are Ardmore Shipping (ASC), TEN, Ltd. (TNP) and International Seaways (INSW).
QD Qudian
$15.85

-1.01 (-5.99%)

11/27/17
STFL
11/27/17
NO CHANGE
Target $19
STFL
Buy
Qudian price target lowered to $19 from $35 at Stifel
Stifel analyst John Davis estimates Alipay's recently announced rate cap could result in as much as a 25% earnings hit to Qudian, but he also believes in that context that the more than 50% correction in the stock is overdone. Headlines about a data leak/breach are unconfirmed, added Davis, who cut his price target on Qudian shares to $19 from $35 but maintains a Buy rating on the stock.
12/05/17
NEED
12/05/17
NO CHANGE
NEED
Qudian price target lowered to $20 from $30 at Needham
Needham analyst Mayank Tandon lowered his price target on Qudian shares to $20 from $30, noting recent news that could create near-term headwinds for the company, including Ant Financial announcing a 24% APR cap for all third-party credit services on its Alipay interface, and PBOC and CRBC releasing a new regulation notice that outlined principles and additional guidelines related to the cash loan business in China. Despite these potential headwinds, Tandon believes Qudian's fundamentals remain in tact, and maintained a Buy rating on Qudian shares.
01/26/18
STFL
01/26/18
DOWNGRADE
STFL
Hold
Qudian downgraded to Hold from Buy at Stifel
01/26/18
01/26/18
DOWNGRADE
Target $15

Hold
Qudian downgraded to Hold amid China cash loan industry turmoil at Stifel
As previously reported, Stifel analyst John Davis downgraded Qudian to Hold from Buy, stating that the near-term outlook is muddied by expected higher credit losses and a significant shift in business model due to the current turmoil in the Chinese cash loan industry. While he thinks Qudian will ultimately benefit from recent regulations in the form of reduced competition, he prefers to move to the sidelines "while the dust settles," he tells investors. Davis lowered his price target on Qudian shares to $15 from $19.
NERV Minerva
$5.75

0.2 (3.60%)

09/01/17
09/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with an Outperform at Bernstein. 2. Minerva (NERV) Neurosciences initiated with a Buy at Citi. 3. VMware (VMW) resumed with a Sector Weight at KeyBanc. 4. Provident Financial (PFS) initiated with a Neutral at DA Davidson. 5. Maximus (MMS) initiated with a Neutral at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/17
SBSH
09/01/17
INITIATION
Target $11
SBSH
Buy
Minerva Neurosciences initiated with a Buy at Citi
Citi analyst Joel Beatty started Minerva Neurosciences with a Buy rating and $11 price target. The Phase 3 trial for lead agent MIN-101 in negative symptoms of schizophrenia is well positioned for success, Beatty tells investors in a research note. He sees negative symptoms of schizophrenia as an attractive market opportunity because there are no approved drugs for the indication.
EGLT Egalet
$0.75

0.02 (2.74%)

09/12/17
CANT
09/12/17
NO CHANGE
Target $7
CANT
Overweight
Investors should consider owning Egalet, says Cantor
Cantor Fitzgerald analyst Brandon Folkes saying the company's five posters at Pain Week last week reinforced the sales potential of, and need for, abuse deterent products such as Arymo ER. With three approved products and a cash runway through 2020, investors should consider owning Egalet shares, Folkes tells investors in a research note. He reiterates an Overweight rating on the shares with a $7 price target.
11/09/17
GABE
11/09/17
DOWNGRADE
GABE
Hold
Egalet downgraded to Hold from Buy at Gabelli
Gabelli analyst Kevin Kedra downgraded Egalet to Hold citing challenges for Arymo, potential generic competition for Sprix, and lack of near-term catalysts.
12/07/17
CANT
12/07/17
NO CHANGE
Target $7
CANT
Overweight
Egalet cash runway through 2020 remains intact, says Cantor Fitzgerald
In a research note titled "You Win Some, You Lose Some; Cash Runway Through 2020 Remains Intact," Cantor Fitzgerald analyst Brandon Folkes says news of CVS (CVS) removing Sprix from its 2018 formulary is a negative for Egalet (EGLT). The development offsets the positive news announced last month that Apotex will not be launching an authorized generic of Sprix in March 2018, Folkes tells investors. He believes, however, that Egalet's cash runway through 2020 remains, even if Sprix revenues in 2018 are reduced by 50%. The analyst thinks Arymo ER is the primary driver of valuation for Egalet. He keeps an Overweight rating on the shares with a $7 price target.
01/03/18
STFL
01/03/18
DOWNGRADE
Target $1.5
STFL
Hold
Egalet downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy downgraded Egalet (EGLT) to Hold from Buy citing the difficult opioid prescribing environment, slow prescription uptake of Arymo ER and headwind from CVS/Caremark's (CVS) formulary exclusion of Sprix. Samimy lowered his price target on Egalet shares to $1.50 from $6.00.
ACRS Aclaris Therapeutics
$21.28

0.72 (3.50%)

02/08/18
GUGG
02/08/18
INITIATION
Target $53
GUGG
Buy
Aclaris Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated Aclaris Therapeutics with a Buy and $53 price target.
09/19/17
CANT
09/19/17
NO CHANGE
Target $50
CANT
Overweight
Public FDA meeting positive for Aclaris, says Cantor
The FDA last Monday conducted a public meeting on alopecia areata patient-focused drug development, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The meeting was constructive on alopecia as a disease and the need to get drugs approved, the analyst contends. She believes the meeting is a positive for Aclaris Therapeutics, which she notes is working on "several solutions to the problem." Chen has an Overweight rating on Aclaris with a $50 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $50
CANT
Overweight
Aclaris Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Aclaris Therapeutics with an Overweight rating and $50 price target.
04/26/17
LEER
04/26/17
NO CHANGE
Target $54
LEER
Outperform
Aclaris patent could be worth $15 per share, says Leerink
Leerink analyst Seamus Fernandez believes the A-101 patent announced today by Aclaris Therapeutics could add $15 per share to the company's net present value. The newly allowed patent expires in 2035, 11 years later than the analyst currently assumes loss of exclusivity in seborrheic keratosis. Extending the patent life of A-101 could increase the NPV contribution to $31 per share from $16, Fernandez tells investors in a research note. He keeps an Outperform rating on Aclaris with a $54 price target.

TODAY'S FREE FLY STORIES

CS

Credit Suisse

$15.22

0.405 (2.73%)

14:25
07/16/18
07/16
14:25
07/16/18
14:25
Options
Credit Suisse call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$39.77

-0.19 (-0.48%)

14:21
07/16/18
07/16
14:21
07/16/18
14:21
Hot Stocks
Beacon Roofing acquires Atlas Supply »

Beacon Roofing Supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$320.52

-1.28 (-0.40%)

, BA

Boeing

$355.82

5.01 (1.43%)

14:17
07/16/18
07/16
14:17
07/16/18
14:17
Periodicals
Talent scarce for defense firms despite jump in military spending, NYT says »

According to the New York…

NOC

Northrop Grumman

$320.52

-1.28 (-0.40%)

BA

Boeing

$355.82

5.01 (1.43%)

LMT

Lockheed Martin

$318.09

-0.35 (-0.11%)

GD

General Dynamics

$191.29

-1.5 (-0.78%)

RTN

Raytheon

$199.63

-0.09 (-0.05%)

UTX

United Technologies

$129.14

-0.4 (-0.31%)

BAESY

BAE Systems

$0.00

(0.00%)

GOOG

Alphabet

$1,186.00

-2.81 (-0.24%)

BABA

Alibaba

$190.58

0.55 (0.29%)

FB

Facebook

$208.14

0.81 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 08

    Aug

  • 10

    Sep

  • 18

    Sep

  • 28

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/16/18
07/16
14:17
07/16/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/16/18
07/16
14:16
07/16/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBG

Hub Group

$49.00

-1.95 (-3.83%)

14:10
07/16/18
07/16
14:10
07/16/18
14:10
Options
Unusually large option print in Hub Group as shares slump »

Unusually large option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:10
07/16/18
07/16
14:10
07/16/18
14:10
General news
Fed's Kashkari worries about the flattening yield curve »

Fed's Kashkari…

JBHT

J.B. Hunt

$120.99

-0.78 (-0.64%)

14:08
07/16/18
07/16
14:08
07/16/18
14:08
Recommendations
J.B. Hunt analyst commentary  »

Loop says J.B. Hunt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

SYRS

Syros Pharmaceuticals

$12.35

(0.00%)

14:08
07/16/18
07/16
14:08
07/16/18
14:08
Conference/Events
Syros Pharmaceuticals to hold a key opinion leader meeting »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

, EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

14:02
07/16/18
07/16
14:02
07/16/18
14:02
Conference/Events
Rice Midstream to host special shareholder meeting »

Special Shareholder…

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

RMP

Rice Midstream

$18.16

0.16 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

CRSP

Crispr Therapeutics

$59.61

-6.13 (-9.32%)

14:01
07/16/18
07/16
14:01
07/16/18
14:01
Periodicals
Crispr Therapeutics tells CNBC does not use methods described in paper »

Crispr Therapeutics told…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$37.79

-0.22 (-0.58%)

14:00
07/16/18
07/16
14:00
07/16/18
14:00
Options
Bullish option play opened in Masco ahead of earnings »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CRSP

Crispr Therapeutics

$59.09

-6.65 (-10.12%)

13:55
07/16/18
07/16
13:55
07/16/18
13:55
Options
Crispr Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
07/16/18
07/16
13:50
07/16/18
13:50
General news
U.S. equities are up from earlier lows »

U.S. equities are up from…

ECA

Encana

$12.84

-0.4 (-3.02%)

13:45
07/16/18
07/16
13:45
07/16/18
13:45
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 09

    Oct

ADS

Alliance Data

$220.17

-23.32 (-9.58%)

13:44
07/16/18
07/16
13:44
07/16/18
13:44
Technical Analysis
Technical Take: Alliance Data comes off the lows of the day »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

CRM

Salesforce

$147.50

-0.18 (-0.12%)

13:39
07/16/18
07/16
13:39
07/16/18
13:39
Hot Stocks
Salesforce announces definitive agreement to acquire Datorama »

Salesforce has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 16

    Aug

YELP

Yelp

$40.33

0.54 (1.36%)

13:35
07/16/18
07/16
13:35
07/16/18
13:35
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBIX

Leading Brands

$1.62

-0.06 (-3.57%)

13:32
07/16/18
07/16
13:32
07/16/18
13:32
Hot Stocks
Leading Brands announces resolution of temporary non-compliance with Nasdaq rule »

Leading Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$22.84

0.2 (0.88%)

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Conference/Events
Stephens agricultural analyst to hold an analyst/industry conference call »

Agriculture, Chemicals,…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

, NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

13:23
07/16/18
07/16
13:23
07/16/18
13:23
Periodicals
Editas tells CNBC 'not specifically concerned about' Crisper study »

Editas Medicine (EDIT)…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$68.30

-0.33 (-0.48%)

13:19
07/16/18
07/16
13:19
07/16/18
13:19
Periodicals
CVS apologizes after store managers call police on black customer, AP says »

CVS Health is apologizing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/16/18
07/16
13:17
07/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/16/18
07/16
13:16
07/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.